Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Alexander O. Schuth Sells 15,558 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander O. Schuth sold 15,558 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total value of $465,339.78. Following the transaction, the insider now owns 178,066 shares of the company’s stock, valued at approximately $5,325,954.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Denali Therapeutics Trading Down 5.4 %

Shares of NASDAQ DNLI traded down $1.69 during midday trading on Tuesday, reaching $29.89. 927,180 shares of the company were exchanged, compared to its average volume of 1,069,046. The stock has a market cap of $4.30 billion, a P/E ratio of -11.44 and a beta of 1.40. The stock has a fifty day simple moving average of $27.95 and a 200 day simple moving average of $23.73. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the firm earned ($0.72) earnings per share. As a group, analysts forecast that Denali Therapeutics Inc. will post -2.62 earnings per share for the current year.

Analyst Ratings Changes

DNLI has been the subject of several recent analyst reports. Bank of America lifted their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Denali Therapeutics in a research note on Thursday, November 7th. JPMorgan Chase & Co. reduced their target price on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Wedbush reduced their target price on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Finally, Citigroup increased their price objective on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $38.90.

Institutional Investors Weigh In On Denali Therapeutics

A number of institutional investors have recently bought and sold shares of DNLI. EP Wealth Advisors LLC acquired a new stake in shares of Denali Therapeutics in the first quarter valued at about $831,000. Edgestream Partners L.P. bought a new position in shares of Denali Therapeutics during the first quarter valued at approximately $2,301,000. Swiss National Bank raised its holdings in shares of Denali Therapeutics by 0.7% during the first quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $4,477,000 after buying an additional 1,500 shares during the last quarter. Bayesian Capital Management LP bought a new stake in shares of Denali Therapeutics during the first quarter valued at about $447,000. Finally, Capital Research Global Investors lifted its position in Denali Therapeutics by 107.9% in the first quarter. Capital Research Global Investors now owns 6,049,957 shares of the company’s stock worth $124,145,000 after purchasing an additional 3,140,429 shares during the period. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.